Trial Profile
A prospective multicentre single-arm non-interventional study evaluating bevacizumab in combination with first-line chemotherapy or HER2-negative Metastatic Breast Cancer.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Jul 2017
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 28 Jul 2017 New trial record
- 20 Jul 2017 Results of pooled analysis of 2 trials ML16684 and ML21165 published in the European Journal of Cancer